In 2008, Lipsic et al. demonstrated that a 3-weekly administration of low-dose EPO (equivalent to 80 U/kg) after myocardial infarction (with a permanent coronary artery ligation) did not raise hematocrit levels but was able to improve cardiac function significantly. The gene discussed is EPO; the disease is myocardial infarction.